Clinical Trial Update: A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 1/Phase 2 study evaluating the combination of amivantamab and docetaxel in participants with metastatic non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING